Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clindamycin Phosphate

FDA-approved product (injectable, injection), marketed as Cleocin, Cleocin Phosphate, Cleocin Phosphate In Dextrose 5% In Plastic Container and 12 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clindamycin Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abdominal abscess
  • Abscess
  • Acne
  • Bacterial disease
  • Bacterial vaginosis
  • Empyema
  • Endometritis
  • Female reproductive system disease
  • Infection
  • Irritable bowel syndrome
  • Lung Abscess
  • Osteomyelitis
  • Parametritis
  • Peritonitis
  • Pneumonia
  • Pseudomembranous enterocolitis
  • and 3 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Antibiotics; Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF01; WHO ATC J01FF01; WHO ATC G01AA10

Repurposing investigation

Clindamycin Phosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clindamycin Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clindamycin Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers

    NCT01915758 · start 2008-11-21

    Registered record
    Registry ID
    NCT01915758
    Conditions
    Acne Vulgaris
    Interventions
    clindamycin1%/tretinoin 0.025% gel; vehicle gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-11-21
    Completion
    2009-02-20
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Interventionclindamycin1%/tretinoin 0.025% gel; vehicle gel
    PhasePhase 1
    Registry statusCompleted

  • Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

    NCT00636935 · start 2008-02

    Registered record
    Registry ID
    NCT00636935
    Conditions
    Pneumocystis Carinii Pneumonia
    Interventions
    Antibiotics only; Antibiotics + Corticosteroids; Corticosteroids + antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-02
    Completion
    2013-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumocystis Carinii Pneumonia
    InterventionAntibiotics only; Antibiotics + Corticosteroids; Corticosteroids + antibiotics
    PhasePhase 4
    Registry statusWithdrawn

  • Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations

    NCT01044264 · start 2007-12

    Registered record
    Registry ID
    NCT01044264
    Conditions
    Acne Vulgaris
    Interventions
    1% Clindamycin/5% Benzoyl Peroxide Topical Gel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-09
    Enrolment
    602

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Intervention1% Clindamycin/5% Benzoyl Peroxide Topical Gel; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Bacterial Vaginosis in Early Pregnancy in Skaraborg and the Effect on Spontaneous Preterm Delivery

    NCT02348463 · start 2007-01

    Registered record
    Registry ID
    NCT02348463
    Conditions
    Bacterial Vaginosis
    Interventions
    Clindamycin-2-phosphate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-01
    Completion
    2014-06
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Vaginosis
    InterventionClindamycin-2-phosphate
    PhaseNot recorded
    Registry statusCompleted

  • Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions

    NCT00836004 · start 2003-11

    Registered record
    Registry ID
    NCT00836004
    Conditions
    Healthy
    Interventions
    Clindamycin 300 mg capsule; Cleocin HCl 300 mg capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-11
    Completion
    2003-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionClindamycin 300 mg capsule; Cleocin HCl 300 mg capsules
    PhasePhase 1
    Registry statusCompleted